Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies

Despite its good initial response and significant survival benefit in patients with castration-resistant prostate cancer (CRPC), taxane therapy inevitably encounters drug resistance in all patients. Deep understandings of taxane resistant mechanisms can significantly facilitate the development of ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Bumbaca, Brandon, Li, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089846/
https://www.ncbi.nlm.nih.gov/pubmed/30109177
http://dx.doi.org/10.1016/j.apsb.2018.04.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089846/
https://www.ncbi.nlm.nih.gov/pubmed/30109177
http://dx.doi.org/10.1016/j.apsb.2018.04.007

Ejemplares similares